AMICUS THERAPEUTICS, INC. — Director's Dealing 2021

Sep 8, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: AMICUS THERAPEUTICS, INC. (FOLD)
CIK: 0001178879
Period of Report: 2021-09-03

Reporting Person: Prout Samantha (Principal Accounting Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-09-03	Common Stock	M	1980	$10.04	Acquired	85150	Direct
2021-09-03	Common Stock	M	2945	$9.55	Acquired	88095	Direct
2021-09-03	Common Stock	S	4925	$12.0139	Disposed	83170	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-09-03	Stock Options (right to buy)	$10.04	M	1980	Disposed	2029-01-02	Common Stock (1980)	Direct
2021-09-03	Stock Options (right to buy)	$9.55	M	2945	Disposed	2030-01-02	Common Stock (2945)	Direct

Footnotes

F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2: This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $12.00 to $12.0650 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3: As of September 3, 2021, 1,980 options were fully vested and exercisable and 3,168 remained unvested from this grant.

F4: As of September 3, 2021, 6,301 options were fully vested and exercisable and 8,826 remained unvested from this grant.